A synthetic GNRH agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Buserelin-NHNH2 (trifluoroacetate salt)

Item No. 24156

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-1-9-luteinizing hormone-releasing factor (swine), hydrazide, 2,2,2-trifluoroacetate
Molecular Formula
C58H83N17O13 • XCF3COOH
Formula Weight
1226.4
Purity
≥95%
Formulation (Request formulation change)
A lyophilized solid
Solubility(Learn about Variance in Solubility)
Water: 1 mg/mlWater: 1 mg/ml
SMILES
OC[C@H](NC([C@@H](NC([C@H](CC1=CNC=N1)NC([C@H]2CCC(N2)=O)=O)=O)CC3=CNC4=C3C=CC=C4)=O)C(N[C@@H](CC5=CC=C(O)C=C5)C(N[C@H](COC(C)(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N6CCC[C@H]6C(NN)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C58H83N17O13.C2HF3O2/c1-31(2)22-40(49(80)67-39(12-8-20-63-57(59)60)56(87)75-21-9-13-46(75)55(86)74-61)68-54(85)45(29-88-58(3,4)5)73-50(81)41(23-32-14-16-35(77)17-15-32)69-53(84)44(28-76)72-51(82)42(24-33-26-64-37-11-7-6-10-36(33)37)70-52(83)43(25-34-27-62-30-65-34)71-48(79)38-18-19-47(78)66-38;3-2(4,5)1(6)7/h6-7,10-11,14-17,26-27,30-31,38-46,64,76-77H,8-9,12-13,18-25,28-29,61H2,1-5H3,(H,62,65)(H,66,78)(H,67,80)(H,68,85)(H,69,84)(H,70,83)(H,71,79)(H,72,82)(H,73,81)(H,74,86)(H4,59,60,63);(H,6,7)/t38-,39+,40+,41+,42+,43+,44+,45-,46+;/m1./s1
InChi Key
KGJOZVCZTNGKDD-IIYAHAGKSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $42

    Add

    5 mg

    $161

    Add

    10 mg

    $262

    Add

    25 mg

    $553

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Buserelin is a synthetic gonadotropin-releasing hormone (GNRH) agonist that is at least 20 times more potent than GNRH.1,2 It is a long-acting agent that, after an initial increase in sex hormone levels, decreases the level of circulating gonadotropins and sex hormones.2 Buserelin (20 µg/kg) reduces tumor growth in a DMBA-induced rat model of mammary cancer.3 It induces enteric neurodegeneration, decreasing the number of luteinizing hormone receptor-positive neurons in the rat gastrointestinal tract, when administered at a dose of 1 mg/kg for 5 days.4 Formulations containing buserelin have been used in the treatment of hormone-dependent prostate cancer and endometriosis.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Conn, P.M., and Crowley, W.F., Jr. Gonadotropin-releasing hormone and its analogs. Annu. Rev. Med. 45, 391-405 (1994).

    2. Sandow, J., von Rechenberg, W., Jerzabek, G., et al. Hypothalamic-pituitary-testicular function in rats after supraphysiological doses of a highly active LRH analogue (buserelin). Acta Endocrinol. (Copenh.) 94(4), 489-497 (1980).

    3. Koibuchi, Y., Sugamata, N., Iino, Y., et al. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer. Int. J. Mol. Med. 4(2), 145-148 (1999).

    4. Sand, E., Voss, U., Hammar, O., et al. Gonadotropin-releasing hormone analog buserelin causes neuronal loss in rat gastrointestinal tract. Cell Tissue Res. 351(3), 521-534 (2013).